Actively Recruiting

Phase 3
Age: 18Years - 75Years
MALE
NCT06350825

Cytoreductive Prostatectomy Combined With Triple or Dual Systemic Therapy in mHSPC Patients

Led by The First Affiliated Hospital with Nanjing Medical University · Updated on 2024-04-05

200

Participants Needed

1

Research Sites

678 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

To evaluate: The radiographic progression-free survival (rPFS) of metastatic hormone-sensitive prostate cancer (mHSPC) patients treated with androgen deprivation therapy (ADT) + second-generation antiandrogens±chemotherapy combined with cytoreductive prostatectomy (CRP)

CONDITIONS

Official Title

Cytoreductive Prostatectomy Combined With Triple or Dual Systemic Therapy in mHSPC Patients

Who Can Participate

Age: 18Years - 75Years
MALE

Eligibility Criteria

Eligible

You may qualify if you...

  • Male aged 18 to 75 years
  • Histologically confirmed prostate adenocarcinoma
  • Evidence of metastasis confirmed by MRI, CT scan, bone scan, or histology
  • Clinical stage M1a, M1b, or M1c
  • No prior local treatment for prostate cancer
  • Surgeon believes prostate can be removed
Not Eligible

You will not qualify if you...

  • Surgeon believes disease is unresectable
  • Life expectancy less than 2 years
  • Active spinal cord compression
  • History of prior local treatment for prostate cancer
  • Difficulty swallowing, chronic diarrhea, intestinal obstruction, or other factors affecting drug intake and absorption
  • Refusal to sign informed consent
  • Investigator believes individual is not suitable for inclusion

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

The First Affiliated Hospital of Nanjing Medical University

Nanjing, Jiangsu, China, 210029

Actively Recruiting

Loading map...

Research Team

L

Lixin Hua, M.D.

CONTACT

S

Shangqian Wang, M.D.,PhD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here